PERCENT SPENDING BY HIV VACCINE RESEARCH AREA, 2017

- Preclinical: 43.6%
- Clinical: 34%
- Basic: 17.6%
- Cohort & site development: 3.8%
- Advocacy & policy: 0.6%
- Social & behavioral: 0.02%

HIV Prevention Research & Development Investments 2017: Investing to End the Epidemic
http://www.hivresourcetracking.org/

www.avac.org
May 2019